Adenosine

6 mg/2 ml and 12 mg/4 ml vials and pre-filled syringes (for rapid IV bolus)

Executive Summary

(August 29, 2023)

Adenosine is an endogenous nucleoside present in all human cells. It is categorized as a so-called “class V” or “miscellaneous” antiarrhythmic agent, as it does not meet the criteria for inclusion in antiarrhythmic classes I, II, III, or IV.


Adult dose for paroxysmal supraventricular tachycardia (7, 8, 13, 14)

“6-12-12 mg”


Comments:

Adult dose

Adult dose for paroxysmal supraventricular tachycardia (7, 8)

“6-12-12 mg”


Comments:

Pediatric dose

Pediatric dose for paroxysmal supraventricular tachycardia (7, 9)

“0.1-0.2-0.2 mg/kg”


Comments:

Indications


Other uses of adenosine in the ED

Mechanism of action and pharmacology


Regular narrow QRS complex tachycardia

Paroxysmal supraventricular tachycardia


PSVT treatment effectiveness summary

Guidelines recommendations


Acute therapy of narrow QRS tachycardia in the absence of an established diagnosis (10). 

Cautions

Pregnancy and lactation

Pregnancy


Pregnancy risk classification


Lactation

References

® 2023 EMDrugs. All rights reserved.

contact@emdrugs.com

DISCLAIMER

This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting. 

 

Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations. 

 

The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are  affiliated. 

 

For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.


EMDrugs Team